This article was originally published in The Gray Sheet
Executive SummaryArthroscopic sports medicine device maker acquires Imagyn Medical Technologies' minimal access surgery product line for approximately $8 mil. Under terms of the agreement announced Nov. 20, Conmed will pay Imagyn $6 mil. up front and an additional $2 mil. over the first year, depending on product sales. The company estimates that the deal will be modestly accretive to overall earnings in 2001
You may also be interested in...
The Chinese government's plan to reduce tariffs it imposed on a slew of US exports is expected to have minimal impact on the overall medtech industry. See what Ralph Ives, AdvaMed's executive VP for global strategy, said about it here.
FDA approved sNDAs from GlaxoSmithKline for diclofenac-containing Voltaren Arthritis Pain for the temporary relief of arthritis pain and from Alcon for Pataday olopatadine drops at 0.2% concentration for once-daily use temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair or dander and 0.1% for twice-daily use for the same indications plus redness relief.